ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Fundamental Analysis
NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD
ARCT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While ARCT seems to be doing ok healthwise, there are quite some concerns on its profitability. ARCT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ARCT has reported negative net income.
In the past year ARCT has reported a negative cash flow from operations.
ARCT had negative earnings in 4 of the past 5 years.
ARCT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -16.90%, ARCT belongs to the best of the industry, outperforming 81.33% of the companies in the same industry.
With an excellent Return On Equity value of -23.92%, ARCT belongs to the best of the industry, outperforming 83.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.9% | ||
| ROE | -23.92% | ||
| ROIC | N/A |
ROA(3y)-18.91%
ROA(5y)-20.7%
ROE(3y)-32.17%
ROE(5y)-43.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ARCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of 1.15, we must say that ARCT is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.15, ARCT is doing good in the industry, outperforming 68.06% of the companies in the same industry.
There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.15 |
ROIC/WACCN/A
WACC9.3%
2.3 Liquidity
ARCT has a Current Ratio of 4.76. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
ARCT has a Current ratio (4.76) which is comparable to the rest of the industry.
A Quick Ratio of 4.76 indicates that ARCT has no problem at all paying its short term obligations.
ARCT has a Quick ratio of 4.76. This is comparable to the rest of the industry: ARCT outperforms 53.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.76 | ||
| Quick Ratio | 4.76 |
3. Growth
3.1 Past
The earnings per share for ARCT have decreased strongly by -189.42% in the last year.
EPS 1Y (TTM)-189.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-246.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-33.01%
3.2 Future
ARCT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.90% yearly.
ARCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.47% yearly.
EPS Next Y27.16%
EPS Next 2Y45.36%
EPS Next 3Y47.32%
EPS Next 5Y44.9%
Revenue Next Year0.3%
Revenue Next 2Y35.48%
Revenue Next 3Y42.55%
Revenue Next 5Y41.47%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ARCT's earnings are expected to grow with 47.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.36%
EPS Next 3Y47.32%
5. Dividend
5.1 Amount
No dividends for ARCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.55
-1.42 (-8.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.76%
Inst Owner Change1.41%
Ins Owners1.37%
Ins Owner Change-0.33%
Market Cap394.16M
Analysts86.67
Price Target68.54 (371.07%)
Short Float %17.05%
Short Ratio10.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)69.89%
Min EPS beat(2)60.74%
Max EPS beat(2)79.04%
EPS beat(4)4
Avg EPS beat(4)56.42%
Min EPS beat(4)17.53%
Max EPS beat(4)79.04%
EPS beat(8)7
Avg EPS beat(8)347.67%
EPS beat(12)10
Avg EPS beat(12)237.61%
EPS beat(16)11
Avg EPS beat(16)170.2%
Revenue beat(2)2
Avg Revenue beat(2)68.47%
Min Revenue beat(2)11.64%
Max Revenue beat(2)125.3%
Revenue beat(4)3
Avg Revenue beat(4)59.34%
Min Revenue beat(4)-11.98%
Max Revenue beat(4)125.3%
Revenue beat(8)6
Avg Revenue beat(8)69.98%
Revenue beat(12)8
Avg Revenue beat(12)161.24%
Revenue beat(16)8
Avg Revenue beat(16)112.68%
PT rev (1m)-3.08%
PT rev (3m)-3.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.81%
EPS NY rev (1m)-1.24%
EPS NY rev (3m)8.84%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-2.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.51 | ||
| P/tB | 1.51 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.01
EYN/A
EPS(NY)-2.19
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS5.92
BVpS9.67
TBVpS9.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.9% | ||
| ROE | -23.92% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-18.91%
ROA(5y)-20.7%
ROE(3y)-32.17%
ROE(5y)-43.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.89% | ||
| Cap/Sales | 0.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.76 | ||
| Quick Ratio | 4.76 | ||
| Altman-Z | 1.15 |
F-Score3
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)296.63%
Cap/Depr(5y)241.64%
Cap/Sales(3y)11%
Cap/Sales(5y)11.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-189.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-246.87%
EPS Next Y27.16%
EPS Next 2Y45.36%
EPS Next 3Y47.32%
EPS Next 5Y44.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-33.01%
Revenue Next Year0.3%
Revenue Next 2Y35.48%
Revenue Next 3Y42.55%
Revenue Next 5Y41.47%
EBIT growth 1Y-230.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.16%
EBIT Next 3Y-29.7%
EBIT Next 5YN/A
FCF growth 1Y64.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.81%
OCF growth 3YN/A
OCF growth 5YN/A